Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Turnaround Potential
1211.4000 -6.60 (-0.54%)
NSE Dec 24, 2025 15:31 PM
Volume: 253.9K
 

1211.40
-0.54%

Aurobindo Pharm

Khambatta Securities
Aurobindos revenues grew 20.1% q-o-q and 17.5% y-o-y to Rs 44,462 mn in 2Q FY18 exceeding our expectations. Revenue growth was driven by 9.9% y-o-y growth in US and 38.6% y-o-y growth in Europe during the quarter. API business also revived during the quarter and grew at a modest 5.0% y-o-y. Adjusted EBITDA increased 30.6% q-o-q and 20.3% y-o-y to Rs 11,276 mn during 2Q FY18. Adjusted EBITDA margin increased 202 bps q-o-q and 58 bps y-o-y to 25.4% in 2Q FY18, exceeding our expectations, mainly due to lower than expected Cost of Goods Sold as percentage of revenues during the quarter....
Promoters pledged 0.42% of shares in last quarter. Total pledge stands at 17.50% of promoter holdings
More from Aurobindo Pharma Ltd.
Recommended